Video Experimental Relacionado
Updated: Feb 26, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.4K
Mejora de la experiencia del usuario con un sistema automatizado de administración de insulina mediante la
Pilar Isabel Beato-Víbora1, Estela Gil-Poch2, Francisco Javier Arroyo-Díez2
1Endocrinology and Nutrition Department, Badajoz University Hospital, Extremadura University, Badajoz, Spain.
Diabetes & vascular disease research
|February 25, 2026
Resumen
La actualización del sensor en un sistema de administración automatizada de insulina (AID) mejoró significativamente la satisfacción del usuario y el control de la glucosa. Esta mejora condujo a un mayor uso del sensor y más tiempo en modo automatizado para pacientes con diabetes tipo 1.
Área de la Ciencia:
- Endocrinología
- Ingeniería Biomédica
- Tecnología de la Diabetes
Sus antecedentes:
- La satisfacción del usuario es clave para los sistemas de administración automatizada de insulina (AID).
- Evaluar los cambios en la satisfacción después de las actualizaciones del sensor es esencial para la optimización del sistema.
Objetivo del estudio:
- Evaluar los cambios en la satisfacción del usuario después de actualizar de Guardian-Sensor®4 a Simplera-Sync™ dentro del sistema AID MiniMed™-780G.
Principales métodos:
- Estudio de intervención prospectivo con 91 participantes con diabetes tipo 1.
- Se evaluó la satisfacción del usuario utilizando el Cuestionario de Experiencia de Monitorización de Glucosa (GME-Q) al inicio y a los 3 meses posteriores a la actualización.
- Se compararon las métricas de control de glucosa y el uso del sistema.
Principales resultados:
- Las puntuaciones globales del GME-Q mejoraron significativamente (de 3,84 a 4,40), y todas las subescalas (eficacia, conveniencia, falta de intrusión) mostraron mejoras.
- El uso del sensor aumentó del 93% al 98%, y el tiempo en modo automático aumentó del 94% al 100%.
- Se observaron reducciones en la hipoglucemia moderada y en los episodios de hipoglucemia en general.
Conclusiones:
- La actualización a un nuevo sensor dentro de un sistema AID mejora la satisfacción del usuario.
- Los nuevos sensores pueden aumentar la utilización del sensor y la duración del modo automático.
- Las mejoras en la experiencia del usuario y el control de la glucosa son alcanzables a través de avances en la tecnología de sensores.
Videos de Conceptos Relacionados
01:27Insulin Formulations: Types and Delivery
871
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
871
01:16Insulin: Dosing Regimen and Adverse Effects
935
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
935
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
50
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
50
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
46
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
46
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.6K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.6K
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
53
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
53